Occurrence and significance of morphologic changes in patients with metastatic triple negative breast cancer treated with Cabozantinib.
To compare performance of RECIST1.1 and Choi criteria in assessment of patients with metastatic triple-negative breast cancer treated with cabozantinib. Thirty patients with metastatic triple-negative breast cancer enrolled in phase 2 clinical trial received cabozantinib. Clinical benefit rates assessed by prospectively determined RECIST1.1 and retrospectively assessed Choi criteria were compared. Decreased tumor density (≥15%) at first follow-up was seen in 22/30(73%) patients. CBR was 40% (95%CI:23-59%) by RECIST1.1, and 73% (95%CI:54-88%) by Choi (NPV=100%, 95%CI:63-100%; PPV=55%, 95%CI:32-76%). Morphologic changes are seen in the majority of patients treated with cabozantinib, making Choi criteria valuable in response assessment.